Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease

Blood

Volumn 89, Issue 12, 1997, Pages 4652-4658

  Tittle, Thomas V ^b   Weinberg, Andrew D ^b   Steinkeler, Cara N ^b   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD45 ANTIGEN; GLYCOPROTEIN; T LYMPHOCYTE ANTIGEN;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0030947611     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4652     Document Type: Article

References (33)

1. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus host disease. Blood 80:2964, 1992
2. den Haan JMM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476, 1995
3. Kelemen E, Szebeni J, Petranyi GG: Graft-versus-host disease in bone marrow transplantation: Experimental, laboratory, and clinical contributions of the last few years. Int Arch Allergy Immunol 102:309, 1993
4. Niederwieser D, Grassegger A, Aubock J, Herold M, Nachbaur D, Rosenmayr A, Gachter A, Nussbaumer W, Gaggl S, Ritter M, Huber C: Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 81:2200, 1993
5. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 84:3603, 1994
6. Keman NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, Flomenberg N, Burns J, Yang SY, Black P, Collins NH, O'Reilly RJ: Graft failure after T cell depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 74:2227, 1989
7. Via CS, Rus V, Gately MK, Finkelman FD: IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol 153:4040, 1994
8. Sykes M, Szot GL, Nguyen PL, Pearson DA: Interleukin-12 inhibits murine graft-versus-host disease. Blood 86:2429, 1995
9. - mediated graft-versus-leukemia effects. Blood 83:2560, 1994
10. Brok HPM, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM: Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 151:6451, 1993
11. Biaise D, Olive D, Him M, Viens P, Lafage M, Attal M, Stoppa AM, Gabert J, Gastaut JA, Camerlo J, Mannoni P, Mawas C, Maraninchi D: Prevention of acute GVDH by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): A feasibility trial in 15 patients. Bone Marrow Transplant 8:105, 1991
12. Belanger C, Esperou-Bourdeau H, Bordigoni P, Jouet JP, Souillet G, Milpied N, Troussard X, Kuentz M, Herve P, Reiffers J, Demeocq F, Dauriac C, Biaise D, Michallet M, Fiere D, Freycon F, Gratecos N, Rio B, Leblond V, Ifrah N, Attai M, Bergerat JP, Vilmer E. Pico J, Raffoux C, Caudrelier P, Gluckman E: Use of anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 11:293, 1993
13. Anasetti C, Martin PJ, Storb R, Appelbaum FR, Beatty PG, Calori E, Davis J, Doney K, Reichert T, Stewart P, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA: Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 7:375, 1991
14. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83:3815, 1994
15. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS: CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 58:602, 1994
16. Gribben JG, Guinan EC, Boussiotis VA, Ke X-Y, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM: Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool. Blood 87:4887, 1996
17. Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, Puklavec M, Williams AF: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 24:1281, 1987
18. Mallett S, Fossum S, Barclay AN: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - A molecule related to nerve growth factor receptor. EMBO 9:1063, 1990
19. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717, 1996
20. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W: Crosslinking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507, 1995
21. Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG: Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 180:757, 1994
22. Baum PR, Gayle RB, Ramsdell F, Srinivasan S, Sorensen RA, Watson ML, Seldin MF, Baker E, Sutherland GR, Clifford KN, Alderson MR, Goodwin RG, Fanslow WC: Molecular characterization of murine and human OX40/OX40 ligand systems: Identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 13:3992, 1994
23. Weinberg AD, Wallin JJ, Jones RE, Sullivan TJ, Bourdette DN, Vandenbark AA, Offner H: Target organ specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with EAE. J Immunol 152:4712, 1994
24. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, Davey M, Palida F, Godfrey W, Engleman E, Fulton RJ, Offner H, Vandenbark AA: Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 2:183, 1996
25. Weinberg AD, Lemon M, Jones AJ, Vainiene M, Celnik B, Buenafe AC, Culbertson N, Bakke A, Vandenbark AA, Offner H: OX-40 antibody enhances for autoantigen specific Vb8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J Neurosci Res 43:42, 1996
26. Schoof DD, Selleck CM, Massaro AF, Jung S-E, Eberlein TJ: Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 50:1138, 1990
27. Chao NJ, Schlegel PG: Prevention and treatment of graft-versus-host disease. Ann N Y Acad Sci 770:130, 1995
28. Fathman CG, Hengartner H: Clones of alloreactive T cells. Nature 272:617, 1978
29. Shiohara T, Narimatsu H, Nagashima M: Induction of cutaneous graft-versus-host disease by allo-or self-la-reactive helper T cells in mice. Transplantation 43:692, 1987
30. Berger M, Wettstein PJ, Korngold R: T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 57:1095, 1994
31. Allen RD, Staley TA, Sidman CA: Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 23:333, 1993
32. Durie F, Fanslow WC, Zappone J, Baum PS, Evans CO, Torrance D, Kennedy MK, Mohler KM: Conversion of chronic graft-versus-host disease to that of acute phenotype using in vivo administration of an antibody to OX40. FASEB J 10:A1435, 1996
33. Smith KA, Cantrell DA: Interleukin 2 regulates its own receptors. Proc Nat Acad Sci USA 82:864, 1985